Lung cancer kills one million people every year around the world and the frequent emergence of resistance to the main basic treatment, platinum compounds, leaves many patients with no real therapeutic option. The most common tumour (~40 %) is adenocarcinoma (Luad) and when the latter is caused by a mutation of the KRAS gene (~30 % of cases), there is no targeted treatment. The project aims to search for biomarkers and therapeutic targets for lung cancer treated with carboplatin using an approach integrating the tumor microenvironment (MET), i.e. all the cells that accompany cancer cells within a tumour. The METCP biomarkers project involves 4 academic partners (INSERM, the University of Montpellier, the University of Toulouse, CHU Toulouse) through the Institut de Recherche en Cancerologie de Montpellier (IRCM) and the Cancer Research Center of Toulouse (CRCT) and the company ACOBIOM, a SME located on the Biopôle Euromédecine in Montpellier, specialising in the discovery of new biological markers and the development of innovative diagnostics for applications in personalised medicine.